ArticleThe Lancet regional health. Western Pacific2023
Antimicrobial susceptibility of bacterial isolates from clinical specimens in four Pacific Island countries, 2017-2021.
Article in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Antimicrobial susceptibility of priority bacterial pathogens from laboratory samples in Timor-Leste: a retrospective analysis of database (2020-2025).The Lancet regional health. Southeast Asia · 2026Article
- Antimicrobial susceptibility trends of WHO critical Gram-negative pathogens in Fijian Hospitals, 2016-2021.JAC-antimicrobial resistance · 2026Article
- Using implementation science to bridge the gaps between political commitment and action in antimicrobial resistance governance under the one health approach in the WHO Southeast Asia and Western Pacific regions.The Lancet regional health. Western Pacific · 2026Review
- Methicillin-resistantThe Lancet regional health. Western Pacific · 2025Review
- Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps.The Lancet regional health. Western Pacific · 2025Review
- Genomic diversity of clinically relevant bacterial pathogens from an acute care hospital in Suva, Fiji.JAC-antimicrobial resistance · 2025Article
- Successful management of a multi-species outbreak of carbapenem-resistant organisms in Fiji: a prospective genomics-enhanced investigation and response.The Lancet regional health. Western Pacific · 2024Article
- Isolation and Characterization of a Bacteriophage with Potential for the Control of Multidrug-ResistantViruses · 2024Article
- Molecular and clinical epidemiology of carbapenem resistantThe Lancet regional health. Western Pacific · 2024Article
- The changing epidemiology of antimicrobial resistance in Fiji: a descriptive analysis of antimicrobial susceptibility and trends of endemic and emerging pathogens, 2019-2022.The Lancet regional health. Western Pacific · 2024Article
- Development of a cross-sectoral antimicrobial resistance capability assessment framework.BMJ global health · 2024Article
- Prevalence and Associated Factors ofAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are limited antimicrobial resistance (AMR) surveillance data from low- and middle-income countries, especially from the Pacific Islands region. AMR surveillance data is essential to inform strategies for AMR pathogen control. Methods: We performed a retrospective analysis of antimicrobial susceptibility results from the national microbiology laboratories of four Pacific Island countries - the Cook Islands, Kiribati, Samoa and Tonga - between 2017 and 2021. We focused on four bacteria that have been identified as 'Priority Pathogens' by the World Health Organization: Findings: Following deduplication, a total of 20,902 bacterial isolates was included in the analysis. The most common organism was Interpretation: Despite challenges, these Pacific Island laboratories were able to conduct AMR surveillance. These data provide valuable contemporary estimates of AMR prevalence, which will inform local antibiotic formularies, treatment guidelines, and national priorities for AMR policy. Funding: Supported by the National Health and Medical Research Council.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.